Table 1 Identifying and transplant data... | American Society of Hematology

Table 1

Identifying and transplant data for patients who underwent T-cell therapy

Patient	Dx	Stage at HCT	Age at HCT, y	Conditioning regimen	GVHD prophylaxis	Acute GVHD	Chronic GVHD	Treatment before T-cell therapy
1	B-ALL	Refractory	42	Cytoxan	Csp, MMF	Skin	Mouth	Vin, Pred, Mito, Ara-C
1	B-ALL	Refractory	42	13.2 Gy TBI	Csp, MMF	Gut	Mouth	Vin, Pred, Mito, Ara-C
2	MDS	RAEB-T	46	Busulfan	Tac, Mtx	Skin	Skin	Ida, Ara-C
2	MDS	RAEB-T	46	Cytoxan	Tac, Mtx	Skin	Skin	Ida, Ara-C
3	B-ALL	Remission	34	Cytoxan	Csp, Mtx	Skin		Ara-C
3	B-ALL	Remission	34	12 Gy TBI	Csp, Mtx	Gut		Ara-C
4	B-ALL	Relapse	41	Cytoxan	Csp, Mtx	Skin	Eyes	Vin, IT, XRT
				Cytoxan			Mouth
				12 Gy TBI			BOOP
5	B-ALL	Refractory	20	Cytoxan	Csp, Mtx	Gut	Eyes	Mtx, Asp, VP-16, Mito
5	B-ALL	Refractory	20	12 Gy TBI	Csp, Mtx	Gut	Mouth	Mtx, Asp, VP-16, Mito
6	MDS	RAEB	46	Busulfan	Csp, Mtx	Skin	Skin	DLI; VP-16, Mito
6	MDS	RAEB	46	Cytoxan	Csp, Mtx	Gut	Skin	DLI; VP-16, Mito
7	B-ALL	Remission	34	Cytoxan	Csp, Mtx	Gut	Skin	FLAG; Mito, Ara-C,VP-16; Dex, Vin, Asp
7	B-ALL	Remission	34	12 Gy TBI	Csp, Mtx	Mouth	Skin	FLAG; Mito, Ara-C,VP-16; Dex, Vin, Asp

Patient	Dx	Stage at HCT	Age at HCT, y	Conditioning regimen	GVHD prophylaxis	Acute GVHD	Chronic GVHD	Treatment before T-cell therapy
1	B-ALL	Refractory	42	Cytoxan	Csp, MMF	Skin	Mouth	Vin, Pred, Mito, Ara-C
1	B-ALL	Refractory	42	13.2 Gy TBI	Csp, MMF	Gut	Mouth	Vin, Pred, Mito, Ara-C
2	MDS	RAEB-T	46	Busulfan	Tac, Mtx	Skin	Skin	Ida, Ara-C
2	MDS	RAEB-T	46	Cytoxan	Tac, Mtx	Skin	Skin	Ida, Ara-C
3	B-ALL	Remission	34	Cytoxan	Csp, Mtx	Skin		Ara-C
3	B-ALL	Remission	34	12 Gy TBI	Csp, Mtx	Gut		Ara-C
4	B-ALL	Relapse	41	Cytoxan	Csp, Mtx	Skin	Eyes	Vin, IT, XRT
				Cytoxan			Mouth
				12 Gy TBI			BOOP
5	B-ALL	Refractory	20	Cytoxan	Csp, Mtx	Gut	Eyes	Mtx, Asp, VP-16, Mito
5	B-ALL	Refractory	20	12 Gy TBI	Csp, Mtx	Gut	Mouth	Mtx, Asp, VP-16, Mito
6	MDS	RAEB	46	Busulfan	Csp, Mtx	Skin	Skin	DLI; VP-16, Mito
6	MDS	RAEB	46	Cytoxan	Csp, Mtx	Gut	Skin	DLI; VP-16, Mito
7	B-ALL	Remission	34	Cytoxan	Csp, Mtx	Gut	Skin	FLAG; Mito, Ara-C,VP-16; Dex, Vin, Asp
7	B-ALL	Remission	34	12 Gy TBI	Csp, Mtx	Mouth	Skin	FLAG; Mito, Ara-C,VP-16; Dex, Vin, Asp

Identifying and transplant data for the 7 patients who underwent T-cell therapy for treatment of recurrent MDS or acute leukemia after MHC-matched allogeneic hematopoietic cell transplantation.

B-ALL indicates B-lineage acute lymphoblastic leukemia; MDS, myelodysplasia; RAEB(-T), refractory anemia with excess blasts (in transformation); TBI, total body irradiation; Csp, cyclosporine; MMF, mycophenolate mofetil; Tac, tacrolimus; Mtx, methotrexate; Vin, vincristine; Pred, prednisone; Mito, mitoxantrone; Ara-C, cytosine arabinoside; IT, intrathecal therapy; XRT, craniospinal radiation; Asp, asparaginase; FLAG, fludarabine, cytosine arabinoside, G-CSF; Dex, dexamethasone; and DLI, donor lymphocyte infusion.

View Large

This Feature Is Available To Subscribers Only